Agreed but I would give them way more credit than
Post# of 158772
(Total Views: 1543)
Posted On: 09/20/2025 5:28:34 PM
Agreed but I would give them way more credit than that. Dr J and company righted a ship that was floundering. Our company is the best bargain in biotech. The value of the company is far far greater than the current, laughable low price of 0.30 would suggest.
Why is it at this low price? There are 37+ million "borrowed" reasons for this laughably low price (per FINRA as of July 15). My sources suggest that the number is now 50+ million "borrowed" reasons (and growing) as to why the price has been manipulated so low when the company pipeline along with its MOA, studies, retrospective data, patents, and CRC trial now started has such tremendous potential.
With average volume of 2 million a day, this is around 25 days to cover folks. This means some hedge funds, day traders, entities, interested third parties, etc have been working hard to keep the price low. That effort will end in failure, and those that have not been wiped out will move on to the next target.
As KenChowder says: "And the milestones to come will be -- most importantly, showing that MOA prospectively instead of retrospectively through raising PD-L1 in the CRC trial. Any benefit that results besides this in the CRC trial will be a help. Showing any progress at all against glioblastoma (pre-clinical) is a milestone to come. Showing any progress at all against Alzheimer's in the privately funded study is a milestone to come. Dr. Sacha initiating the Latch trial is a milestone. Advances in the triple-therapy cure for HIV -- like a human trial, which Sacha has said he intends to pursue -- will be a milestone."
Right on. With new data coming, I view this as an opportunity to accumulate more shares from those who borrowed their shares and don't know what they have, or have a vested interested in a low price, or have a strategic interest in limiting sources of funding.
The ship that was once floundering is clearly headed to open waters and far better to be onboard.
Keep on keeping on.
Staying long for the long haul
Why is it at this low price? There are 37+ million "borrowed" reasons for this laughably low price (per FINRA as of July 15). My sources suggest that the number is now 50+ million "borrowed" reasons (and growing) as to why the price has been manipulated so low when the company pipeline along with its MOA, studies, retrospective data, patents, and CRC trial now started has such tremendous potential.
With average volume of 2 million a day, this is around 25 days to cover folks. This means some hedge funds, day traders, entities, interested third parties, etc have been working hard to keep the price low. That effort will end in failure, and those that have not been wiped out will move on to the next target.
As KenChowder says: "And the milestones to come will be -- most importantly, showing that MOA prospectively instead of retrospectively through raising PD-L1 in the CRC trial. Any benefit that results besides this in the CRC trial will be a help. Showing any progress at all against glioblastoma (pre-clinical) is a milestone to come. Showing any progress at all against Alzheimer's in the privately funded study is a milestone to come. Dr. Sacha initiating the Latch trial is a milestone. Advances in the triple-therapy cure for HIV -- like a human trial, which Sacha has said he intends to pursue -- will be a milestone."
Right on. With new data coming, I view this as an opportunity to accumulate more shares from those who borrowed their shares and don't know what they have, or have a vested interested in a low price, or have a strategic interest in limiting sources of funding.
The ship that was once floundering is clearly headed to open waters and far better to be onboard.
Keep on keeping on.
Staying long for the long haul
(15)
(0)